ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
WALTHAM, Mass., Jan. 27, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period ended December 31, 2011 – the second quarter of the Company's 2012 fiscal year.